Detects human IL-15 in direct ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) IL-1 alpha, -1 beta, -2, -3, -4, -5, -6, -7, -8, -9, rmIL-1 alpha, -1 beta, -3, -4, -5, -6, -7, -9, or -13 is observed.
Monoclonal Mouse IgG1 Clone # 34505
Protein A or G purified from hybridoma culture supernatant
E. coli-derived recombinant human IL-15 Asn49-Ser162 Accession # P40933
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human IL-15 Protein (Catalog #
Measured by its ability to neutralize IL‑15-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The Neutralization Dose (ND50) is typically 4-20 ng/mL in the presence of 3 ng/mL Recombinant Human IL‑15.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Cell Proliferation Induced by IL‑15 and Neutralization by Human IL‑15 Antibody.
Recombinant Human IL‑15 (Catalog # 247-ILB) induces proliferation in the MO7e human megakaryocytic leukemic cell line in a dose-dependent manner (orange line), as measured by the Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IL‑15 (3 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Primate IL‑15 Monoclonal Antibody (Catalog # MAB647). The ND50 is typically 4-20 ng/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Interleukin 15 (IL-15) is a widely expressed 14 kDa cytokine that is structurally and functionally related to IL-2 (1-3). Mature human IL-15 shares 70% amino acid sequence identity with mouse and rat IL-15. Alternate splicing generates isoforms of IL-15 with either a long or short signal peptide (LSP or SSP), and the SSP isoform is retained intracellularly (4). IL-15 binds with high affinity to IL-15 R alpha (5). It binds with lower affinity to a complex of IL-2 R beta and the common gamma chain ( gamma c) which are also subunits of the IL-2 receptor complex (1, 6). IL-15 associates with IL-15 R alpha in the endoplasmic reticulum, and this complex is expressed on the cell surface (7, 8). The dominant mechanism of IL-15 action is known as transpresentation in which IL-15 and IL-15 R alpha are coordinately expressed on the surface of one cell and interact with complexes of IL-2 R beta / gamma c on adjacent cells (9). This enables cells to respond to IL-15 even if they do not express IL-15 R alpha (8, 10). Soluble IL-15-binding forms of IL-15 R alpha can be generated by proteolytic shedding or alternate splicing (11-13). These molecules retain the ability to bind tightly to IL-15 and can either inhibit or augment IL-15 function (5, 12, 13). Consistent with its shared use of IL-2 receptor subunits, IL-15 induces IL-2-like effects in lymphocyte development and homeostasis (3). It is particularly important for the maintenance and activation of NK cells and CD8+ memory T cells (3). IL-15 also exerts pleiotropic effects on other hematopoietic cells and non-immune cells (2). Ligation of membrane-associated IL-15/IL-15 R alpha complexes induces reverse signaling that promotes cellular adhesion, tyrosine phosphorylation of intracellular proteins, and cytokine secretion by the IL-15/IL-15 R alpha expressing cells (14, 15).
Grabstein, K. et al. (1994) Science 264:965.
Budagian, V. et al. (2006) Cytokine Growth Factor Rev. 17:259.
Ma, A. et al. (2006) Annu. Rev. Immunol. 24:657.
Tagaya, Y. et al. (1997) Proc. Natl. Acad. Sci. USA 94:14444.
Giri, J.G. et al. (1995) EMBO 14:3654.
Giri, J. et al. (1994) EMBO J. 13:2822.
Duitman, E.H. et al. (2008) Mol. Cell. Biol. 28:4851.
Dubois, S. et al. (2002) Immunity 17:537.
Stonier, S.W. and K.S. Schluns (2010) Immunol. Lett. 127:85.
Burkett, P.R. et al. (2004) J. Exp. Med. 200:825.
Budagian, V. et al. (2004) J. Biol. Chem. 279:40368.
Mortier, E. et al. (2004) J. Immunol. 173:1681.
Bulanova, E. et al. (2007) J. Biol. Chem. 282:13167.
Budagian, V. et al. (2004) J. Biol. Chem. 279:42192.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you
include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image.
Limited to verified customers in USA, Canada and Europe.
Read what people are saying who have used Human/Primate IL-15 Antibody.
We have 1 review tested in 1 species: Human.
We have 1 review tested in 1 application: ELISA.